Figure 8
From: TAK1 inhibition prevents the development of autoimmune diabetes in NOD mice
TAK1 inhibitor delays the onset and decreases the incidence of autoimmune diseases in CY-accelerated NOD mice.
Accelerated autoimmune diabetes onset was studied in 9-week-old female NOD mice receiving single cyclophosphamide (CY; 200 mg/kg; Sigma-Aldrich) injection intraperitoneally. Experimental groups received OZ at doses of 15 μg or 30 μg/mouse starting 1 week before CY once a week for 4 weeks, respectively. *P < 0.05, compared with PBS-treated NOD mice.
